2 people like this post.

Share

child in Europe has become the second individual ever to receive a commercial gene therapy, according to GlaxoSmithKline.

The treatment, called Strimvelis, can provide an outright cure for a rare inherited immune deficiency by revising a patient’s genetic makeup (see “Gene Therapy’s First Out-and-Out Cure Is Here”).

Gene therapy has been widely explored in experimental medical studies, but its commercial potential is largely untested. Prior to now, only a single other individual, also from Europe, had ever accessed gene therapy to treat an inherited ailment outside of a clinical trial. That individual received a different drug, Glybera, in 2015.

… Read More

2 people like this post.

Share
MIT Technology Review

Tags: , , , , , ,

Leave a Reply